

Eudor-a: a Naturalistic, European Multi-centre Clinical Study of Edor Test in Adult Patients with Primary Depression

M. Sarchiapone¹, M. Iosue¹, M. Amore², E. Baca-Garcia³, A. Batra⁴, S. Bauer⁵, D. Cosman⁶, P. Courtet⁷, G. Di Sciascio⁸, P. Girardi⁹, R. Gusmão¹⁰, W. Kaschka¹¹, T. Parnowski¹², Z. Rihmer¹³, P. Saiz¹⁴, J. Thome¹⁵, A. Tingström¹⁶, M. Wojnar¹⁷, P. Zeppegno¹⁸, L.H. Thorell¹⁹, C. Holmberg¹⁹

¹Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy ; ²Department of Neuroscience DINOGMI, University of Genoa, Genoa, Italy ; ³Department of Psychiatry, Fundacion Jimenez Diaz University Hospital, Madrid, Spain ; ⁴Department of Psychiatry and Psychotherapy, University Hospital Tuebingen, Tuebingen, Germany ; ⁵Department of Psychiatry, Landeskrankenhaus Rankweil, Rankweil, Austria ; ⁶Department of Clinical Psychology and Mental Health, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania ; ⁷Department of Psychiatry and Medical Psychology, University Hospital of Montpellier, Montpellier, France ; ⁸Department of Psychiatry, University of Bari, Bari, Italy ; ⁹Department of Psychiatry, Sapienza University, Rome, Italy ; ¹⁰Department of Psychiatry, Egas Moniz Hospital, Lisbon, Portugal ; ¹¹Zentrum für Psychiatrie Südwürttemberg, Zentrum für Psychiatrie Südwürttemberg, Ravensburg, Germany ; ¹²II Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii, Warsaw, Poland ; ¹³National Institute of Psychiatry and Addictions, National Institute of Psychiatry and Addictions, Budapest, Hungary ; ¹⁴Department of Psychiatry, University of Oviedo, Oviedo, Spain ; ¹⁵Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsmedizin Rostock, Rostock, Germany ; ¹⁶Department of Psychiatry, Lund University, Lund, Sweden ; ¹⁷First Psychiatric Clinic, Medical University of Warsaw, Warsaw, Poland ; ¹⁸Department of Psychiatry, "Amedeo Avogadro" Piemonte Orientale University, Novara, Italy ; ¹⁹EMOTRA AB, EMOTRA AB, Göteborg, Sweden

Introduction: Previous findings suggested that electrodermal hyporeactivity has a high sensitivity (up to 97%) and high raw specificity (up to 98%) for suicide.

Aim: To evaluate prevalence, sensitivity and specificity of electrodermal hyporeactivity for suicide and suicide attempt, with and without death intent and with violent method or not, in adult patients with a primary diagnosis of depression.

Methods: At each study site at least 100 patients with a primary diagnosis of depression, also in remission, will be recruited. Depressive symptomatology will be evaluated through the Montgomery-Asberg Depression Scale. Previous suicide attempts will be registered and the death intent of the worst attempt will be rated according to the first eight items of the Beck Suicide Intent Scale. The risk of suicide will be assessed according to rules and traditions at the centre. The EDOR Test (ElectroDermal Orienting Reactivity) will be performed. Two fingers are put on gold electrodes. Through headphones a moderately strong tone is presented now and then during the test. Sensors located within the electrodes are able to register the electrodermal response to those tones, measuring the skin conductance (i.e. electrodermal activity from sweat gland activity). Each patient will be followed up for one year for actions of intentional self-harm that require medical care and for suicide. The death intent will also be rated.

Expected results: It is expected that the EDOR test detects a previously unknown neuropsychological dysfunction that is independent of the depressive state and can predict suicidality with a high sensitivity and specificity.